Milestone Pharmaceuticals (MIST) Competitors $1.72 +0.02 (+0.88%) As of 03:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIST vs. ABEO, OLMA, ALDX, AMRN, BNTC, RCKT, INBX, NGNE, CADL, and LRMRShould you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Abeona Therapeutics (ABEO), Olema Pharmaceuticals (OLMA), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Benitec Biopharma (BNTC), Rocket Pharmaceuticals (RCKT), Inhibrx Biosciences (INBX), Neurogene (NGNE), Candel Therapeutics (CADL), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry. Milestone Pharmaceuticals vs. Its Competitors Abeona Therapeutics Olema Pharmaceuticals Aldeyra Therapeutics Amarin Benitec Biopharma Rocket Pharmaceuticals Inhibrx Biosciences Neurogene Candel Therapeutics Larimar Therapeutics Milestone Pharmaceuticals (NASDAQ:MIST) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations. Does the media prefer MIST or ABEO? In the previous week, Abeona Therapeutics had 4 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 15 mentions for Abeona Therapeutics and 11 mentions for Milestone Pharmaceuticals. Abeona Therapeutics' average media sentiment score of 0.77 beat Milestone Pharmaceuticals' score of -0.06 indicating that Abeona Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abeona Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, MIST or ABEO? Milestone Pharmaceuticals has higher earnings, but lower revenue than Abeona Therapeutics. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMilestone Pharmaceuticals$1M91.68-$41.52M-$0.84-2.04Abeona Therapeutics$3.50M102.05-$63.73M$0.709.95 Do insiders & institutionals hold more shares of MIST or ABEO? 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 19.5% of Milestone Pharmaceuticals shares are held by company insiders. Comparatively, 5.4% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer MIST or ABEO? Milestone Pharmaceuticals presently has a consensus target price of $7.00, suggesting a potential upside of 308.16%. Abeona Therapeutics has a consensus target price of $19.50, suggesting a potential upside of 179.97%. Given Milestone Pharmaceuticals' higher probable upside, equities analysts clearly believe Milestone Pharmaceuticals is more favorable than Abeona Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Milestone Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is MIST or ABEO more profitable? Abeona Therapeutics' return on equity of 150.05% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Milestone PharmaceuticalsN/A -1,672.29% -83.09% Abeona Therapeutics N/A 150.05%59.86% Which has more risk & volatility, MIST or ABEO? Milestone Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. SummaryAbeona Therapeutics beats Milestone Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIST vs. The Competition Export to ExcelMetricMilestone PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$91.68M$3.13B$5.72B$9.77BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-2.0420.9330.9025.26Price / Sales91.68231.60403.8188.28Price / CashN/A41.5625.2228.45Price / Book6.869.749.516.00Net Income-$41.52M-$54.74M$3.26B$265.34M7 Day Performance10.65%7.94%4.48%2.84%1 Month Performance8.54%7.52%5.19%1.58%1 Year Performance27.99%17.41%31.75%25.40% Milestone Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MISTMilestone Pharmaceuticals1.4435 of 5 stars$1.72+0.9%$7.00+308.2%+26.9%$91.68M$1M-2.0430Earnings ReportAnalyst RevisionABEOAbeona Therapeutics4.5665 of 5 stars$6.28+0.3%$19.25+206.5%+42.6%$320.24M$3.50M-4.9490News CoverageEarnings ReportAnalyst ForecastOLMAOlema Pharmaceuticals2.1336 of 5 stars$4.57-1.5%$24.50+436.1%-54.9%$317.48MN/A-2.2770Earnings ReportALDXAldeyra Therapeutics2.0457 of 5 stars$5.25-0.2%$9.50+81.0%+6.3%$315.05MN/A-6.1810AMRNAmarin0.254 of 5 stars$14.94-0.3%$12.00-19.7%+26.9%$310.40M$228.61M-4.07360Positive NewsBNTCBenitec Biopharma1.7364 of 5 stars$11.90+0.8%$26.00+118.5%+47.7%$309.76M$80K-7.8820News CoveragePositive NewsRCKTRocket Pharmaceuticals4.8489 of 5 stars$2.92+2.1%$16.33+459.4%-83.9%$308.61MN/A-1.16240INBXInhibrx Biosciences1.6532 of 5 stars$21.40+1.6%N/A+87.2%$304.86M$200K0.18166News CoveragePositive NewsEarnings ReportAnalyst UpgradeShort Interest ↓NGNENeurogene2.001 of 5 stars$20.35-4.1%$46.17+126.9%-41.4%$302.64M$930K-4.6890Earnings ReportCADLCandel Therapeutics2.6082 of 5 stars$6.21+3.2%$22.00+254.3%+15.6%$301.62M$120K-4.6360Earnings ReportLRMRLarimar Therapeutics2.4599 of 5 stars$3.78+5.6%$18.50+389.4%-47.2%$296.35MN/A-2.5430News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies ABEO Alternatives OLMA Alternatives ALDX Alternatives AMRN Alternatives BNTC Alternatives RCKT Alternatives INBX Alternatives NGNE Alternatives CADL Alternatives LRMR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIST) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access